TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30991863
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (chemotherapy only: taxane, irinotecan, and fluorouracil)
Study: 23019834
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (10 mg/5 mL concentration)
Study: 8586837
Drug: HIV-1 infected
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HIV-1 infected patients with oral hairy leukoplakia
Study: 2670657
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg o.d.)
Study: 68225
Drug: Subcuticular polyglycolic
Normalized name: polyglycolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcuticular polyglycolic acid (P.G.A.) sutures
Study: 31264313
Drug: 1-g hesperidin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g hesperidin capsule
Study: 28514320
Drug: 20 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 minutes of forced air warming plus intravenous fluid warming
Study: 28514320
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active preoperative warming plus intravenous fluid warming
Study: 27870739
Drug: Angle Labor
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angle Labor Pain Questionnaire (A‐LPQ) administered before epidural insertion (Test 1)
Study: 27870739
Drug: Angle Labor
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angle Labor Pain Questionnaire (A‐LPQ) administered 20 to 30 minutes after test dose (Test 2)
Study: 20533147
Drug: Microcurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent therapy (M)
Study: 8175973
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (S)
Study: 15286546
Drug: Sivelestat (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivelestat (0.16 mg.kg(‐1)hr(‐1))
Study: 9263388
Drug: Intravenously and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously and orally administered trimethoprim
Study: 8112375
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg per day)
Study: 3771809
Drug: l-norepinephrine infusion
Normalized name: L-Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-norepinephrine infusion (4 to 16 micrograms/min)
Study: 27206497
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) preoperative intervention
Study: 24990275
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (40 g, >85% cocoa)
Study: 24990275
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate (40 g, ≤35% cocoa)
Study: 16020940
Drug: Virgin argan
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin argan oil (VAO) 25 g/day for 3 weeks
Study: 16020940
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin olive oil (EVO) 25 g/day for 3 weeks
Study: 14623832
Drug: Crutches, early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crutches, early weight bearing, and non-steroidal anti-inflammatory drugs
Study: 8874336
Drug: Psychologic distress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychologic distress screening program with monthly telephone screening and additional psychosocial intervention for high distress patients
Study: 8874336
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving brief psychosocial intervention from a social worker at initial treatment
Study: 8874336
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group receiving brief psychosocial intervention from a social worker at initial treatment
Study: 8874336
Drug: Minimal psychosocial
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal psychosocial intervention at initial treatment
Study: 1997689
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (4 courses at 28-day intervals of 100 mg/M2 cisplatin, 60 mg/M2 doxorubicin, and 600 mg/M2 cyclophosphamide)
Study: 6394405
Drug: Ionization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionization with diclofenac sodium (150 mg)
Study: 6394405
Drug: Placebo (ionization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ionization with saline solution)
Study: 30867067
Drug: Prebiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic supplementation (10 g/day for healthy subjects, 20 g/day for frail subjects)
Study: 30867067
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 g/day maltodextrin)
Study: 24970377
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (100 ml for women, 200 ml for men)
Study: 22516873
Drug: Sequential ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential ART interruptions (arm 2)
Study: 19681410
Drug: Subarachnoid morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid morphine, bupivacaine and fentanyl
Study: 19681410
Drug: Subarachnoid morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid morphine and bupivacaine
Study: 19681410
Drug: Subarachnoid morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid morphine only
Study: 11283049
Drug: double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: double dose of proton pump inhibitor
Study: 9133967
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate (GSTM) 50 mg weekly
Study: 12369757
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg
Study: 24876490
Drug: Psychosocial stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial stimulation intervention (weekly visits from community health workers for 2 years)
Study: 21092774
Drug: Thoracic endovascular
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic endovascular aortic repair (TEVAR) with optimal medical therapy (n = 72)
Study: 21092774
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (n = 68)
Study: 12867220
Drug: IM fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IM fulvestrant 50 mg
Study: 12867220
Drug: IM fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IM fulvestrant 125 mg
Study: 12867220
Drug: IM fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IM fulvestrant 250 mg
Study: 12867220
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen 20 mg
Study: 12906937
Drug: 5mg prednisolone
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg prednisolone daily
Study: 10220832
Drug: Gly‐X‐Y repeat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gly‐X‐Y repeat sequences (active drug)
Study: 7838040
Drug: Regimen A1
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A1 followed by alternating treatment with regimen B and intensified A1 (group 1)
Study: 7838040
Drug: Regimen A1
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A1 followed by alternating treatment with regimen C and intensified A1 (group 2)
Study: 7838040
Drug: Supralethal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supralethal therapy and bone marrow transplantation (BMT) (group 3)
Study: 2115044
Drug: 6 x
Normalized name: Mepilex AG 6 x 6"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 x 100 mg testosterone pellets
Study: 2115044
Drug: 6 x
Normalized name: Mepilex AG 6 x 6"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 x 200 mg testosterone pellets
Study: 2115044
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 200 mg testosterone pellets
Study: 2115044
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg testosterone pellets
Study: 342729
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid therapy at a dosage of 15 mg/kg/day or more
Study: 342729
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid therapy at a dosage of less than 15 mg/kg/day
Study: 29843840
Drug: Emergency Department
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency Department (ED) treatment services
Study: 17097276
Drug: Antipsychotic withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic withdrawal
Study: 17097276
Drug: Chronic stable
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic stable antipsychotic treatment
Study: 17097276
Drug: Medication withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication withdrawal
Study: 8426406
Drug: Moxisylyte (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxisylyte (10 mg)
Study: 8426406
Drug: Moxisylyte (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxisylyte (20 mg)
Study: 8426406
Drug: Moxisylyte (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxisylyte (30 mg)
Study: 3119443
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch system with discontinuous drug release (7.5 mg/24 hours)
Study: 24579284
Drug: PerioBalance (Lactobacilli
Approvals — FDA: no, EMA: no, PMDA: no
Description: PerioBalance (Lactobacilli reuteri‐CFU of 200 million) lozenges for 28 days
Study: 24579284
Drug: EvoraKids (Streptococcus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EvoraKids (Streptococcus uberis KJ2, Streptococcus oralis KJ3, Streptococcus rattus JH1 45, > or = 100 million) probiotics chewable tablets for 30 days
Study: 11350463
Drug: Dolasetron 50
Normalized name: dolasetron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 50 mg orally
Study: 2686713
Drug: Zofenopril (ZOF),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril (ZOF), 30 mg, once daily (n = 18)
Study: 2686713
Drug: Hydrochlorothiazide (HCT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT), 25 mg, once daily (n = 19)
Study: 23549581
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg daily (initially 30 mg for 1 week, then 60 mg for 4 weeks)
Study: 21799214
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g/kg BM)
Study: 18645344
Drug: Cold pressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold pressor test (CPT) with 0.9% saline solution infusion
Study: 16437735
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine regimen (Sang Ju Yin and Yu Ping Feng San) taken orally for 14 days
Study: 16437735
Drug: Control study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control study without TCM treatment
Study: 10711928
Drug: Aerosol Edmonston‐Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol Edmonston‐Zagreb vaccine
Study: 10711928
Drug: Subcutaneous Edmonston‐Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Edmonston‐Zagreb vaccine
Study: 10711928
Drug: Subcutaneous Schwarz
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Schwarz vaccine
Study: 10711928
Drug: Aerosol Schwarz
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol Schwarz vaccine
Study: 9180629
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol intake (1.0 g/kg body wt)
Study: 27737361
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy (Infrared laser, AsGaAI, wavelength of 790 nm, output power of 20 mW, fluence of 6 J/cm2)
Study: 21729372
Drug: Energy-protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-protein supplementation (one or six biscuits daily for 60 days)
Study: 20134330
Drug: Lopinavir/ritonavir 800/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 800/200 mg QD
Study: 20134330
Drug: Lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 400/100 mg BID
Study: 9555757
Drug: Montelukast (5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5-mg chewable tablet) once daily at bedtime for 8 weeks
Study: 9555757
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily at bedtime for 8 weeks
Study: 28509904
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy emphasizing exercise during behavioral activation (CBT-E)
Study: 28509904
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy with pleasurable low-energy activities (CBT-C)
Study: 21167340
Drug: IRA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IRA infusion of 10 million CD34(+) cells
Study: 21167340
Drug: IRA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IRA infusion of 5 million CD34(+) cells
Study: 21167340
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no CD34(+) cell infusion)
Study: 10828934
Drug: Multinutrient liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multinutrient liquid supplement
Study: 1586984
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) 200 mg/m2 alone
Study: 1586984
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) 200 mg/m2 in combination with recombinant human TNF-alpha (rhTNF alpha) 88 micrograms/m2
Study: 1586984
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) in combination with TNF
Study: 29338751
Drug: Conventional didactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional didactic drug prevention course (2 sessions)
Study: 22585378
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of oral prednisolone
Study: 18356189
Drug: Active-Passive Bilateral
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-Passive Bilateral Therapy (APBT) for 10-15 min prior to self-directed motor practice
Study: 18356189
Drug: Active-Passive Bilateral
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-Passive Bilateral Therapy (APBT)
Study: 17265483
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg subcutaneously every other week)
Study: 12487388
Drug: Saquinavir SGC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir SGC 1200 mg three-times daily plus two NRTIs (arm A)
Study: 12487388
Drug: Saquinavir SGC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir SGC 1600 mg twice-daily plus two NRTIs (arm B)
Study: 12487388
Drug: Saquinavir SGC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily plus a single NRTI (arm C)
Study: 12487388
Drug: Saquinavir SGC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir SGC 1600 mg twice-daily (arm B)
Study: 12487388
Drug: Saquinavir SGC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily (arm C)
Study: 12487388
Drug: Saquinavir SGC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir SGC 1200 mg three-times daily (arm A)
Study: 7783096
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 240 mg once daily
Study: 6085365
Drug: Nitrendipine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20-40 mg/day)
Study: 6085365
Drug: Oxprenolol (160-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (160-320 mg/day)
Study: 31381365
Drug: Competency-Based Approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Competency-Based Approaches to Community Health (COACH) intervention, consisting of 15 weekly, 90-minute sessions followed by 3 months of twice-monthly health coaching calls.
Study: 31381365
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving a twice-monthly school readiness curriculum for 3 months.
Study: 25252515
Drug: Structured behavioural
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured behavioural management and pharmacological treatment
Study: 22372512
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg molindone (5 mg if weight <30 kg)
Study: 22372512
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg molindone (10 mg if weight <30 kg)
Study: 22372512
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg molindone (15 mg if weight <30 kg)
Study: 22372512
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg molindone (20 mg if weight <30 kg)
Study: 18271234
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Haloperidol orally)
Study: 16898430
Drug: Experimental mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental mouthwash formulation
Study: 15255163
Drug: Irinotecan, cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan, cisplatin, and etoposide (IPE) administered every 4 weeks (arm B)
Study: 3158320
Drug: Triphasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic preparation containing levonorgestrel + ethinylestradiol
Study: 31859087
Drug: Collagen-based supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-based supplement (1000 kcal)
Study: 28106331
Drug: High-dose antivenom
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antivenom (20 vials)
Study: 28106331
Drug: Low-dose antivenom
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antivenom (10 vials) plus 4 U of fresh frozen plasma (FFP)
Study: 25929712
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapies)
Study: 18645050
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg slow-release, once daily)
Study: 17074656
Drug: FEC50 (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC50 (fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2), 6 cycles every 21 days)
Study: 17074656
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no systemic treatment)
Study: 10993030
Drug: 17beta-estradiol 1
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol 1 mg
Study: 10993030
Drug: 17beta-estradiol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-estradiol 0.5 mg
Study: 3909321
Drug: Intravenous aztreonam
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aztreonam (1-2 g every 8 hr)
Study: 3909321
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin (3-5 mg/kg per day)
Study: 26922019
Drug: Lung protective
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung protective ventilation (VT of 6 mL/kg + RMs + PEEP: 5 cmH(2)O (PBW) and RR of 12‐18 /min)
Study: 26922019
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (VT of 10 mL/kg (PBW) and RR of 10‐12 /min)
Study: 24346821
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1000 mg
Study: 11290878
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 400 mg
Study: 14975052
Drug: T‐piece mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: T‐piece mode (4 l/min oxygen via a T‐piece for 2 hours)
Study: 8214998
Drug: Weight-based heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based heparin nomogram (starting dose, 80 units/kg body weight bolus, 18 units/kg per hour infusion)